Olema Pharmaceuticals: Investor Conference Presentations – February 2026

Olema Oncology to Present at Key Investor Conferences in February 2026

Olema Oncology (Nasdaq: OLMA), a biopharmaceutical company pioneering targeted therapies for breast cancer, will share updates on its clinical programs at three prominent investor events next month.

San Francisco,CA – February 4,2026 – Olema Pharmaceuticals,Inc., operating as olema Oncology, announced today its participation in teh Guggenheim Securities Emerging Outlook: Biotech Summit, Citi’s 2026 Virtual Oncology Leadership Summit, and the Oppenheimer 36th Annual Healthcare Life Sciences Conference. These presentations will offer investors a deeper look into the company’s progress in developing innovative treatments for breast cancer and other cancers.

Did you know? – Estrogen receptor-positive breast cancer is the most common type of breast cancer, accounting for approximately 80% of all cases. Olema Oncology’s research focuses on targeting this receptor to improve treatment outcomes.

Investor Conference Schedule

Olema Oncology will participate in the following conferences:

• Guggenheim Securities Emerging Outlook: Biotech Summit – February 11, 2026, at 10:00 a.m. ET in New York, NY. The format will be a fireside chat.
• Citi’s 2026 Virtual Oncology Leadership Summit – February 19, 2026, at 1:00 p.m.ET. This event will be held virtually and will feature a fireside chat format.
• Oppenheimer 36th Annual Healthcare Life Sciences Conference – February 26, 2026, at 8:00 a.m. ET.This conference will be virtual and will also be conducted as a fireside chat.

Live webcasts and recordings of these presentations, subject to host permissions, will be accessible in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

Pro tip – Fireside chats are informal presentations that allow investors to engage directly with company leadership and ask questions about strategy and progress.

Advancing a Pipeline of Novel Therapies

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to improving outcomes for patients with breast cancer and beyond. The company’s research focuses on endocrine-driven cancers, nuclear receptors, and the mechanisms of acquired resistance.

The company’s lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being evaluated in two Phase 3 clinical trials. Olema is also developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, which is currently in a Phase 1 clinical study.

According to a company release, Olema Oncology is committed to “transforming the standard of care and improving outcomes” for cancer patients. The company maintains its headquarters in San Francisco, California, with additional operations in Cambridge, massachusetts.

Reader question – What is the difference between a CERAN and a SERD? Both target the estrogen receptor, but SERDs actively degrade the receptor, potentially offering a more complete blockade.

For media and investor relations inquiries, please contact:

Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
[email protected]

For more information a